Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 149 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03958240Recruiting
Study how cancers trigger the immune system
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
ToulouseAges 18 years+ - NCT04219813Recruiting
Test for gluten peptides in urine for non-celiac gluten sensitivity
This study looks for specific “gluten fragments” (immunogenic peptides) in urine to see if they can detect non-celiac gluten/wheat sensitivity. It may help confirm what’s driving symptoms in people who already avoid gluten.
Palermo, PalermoAges 18–75 - NCT04422366RecruitingPhase 3
9-valent HPV vaccine study for healthy Chinese women
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
Liuzhou, GuangxiAges 20–45 - NCT04446832Recruiting
Vaccine study for people waiting for liver transplant
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
LyonAges 18 years+ - NCT04460235RecruitingPhase 4
Compare two pneumococcal vaccines in adults treated for lymphoma
This trial compares two vaccination plans to see which one works better for preventing pneumococcal infections after lymphoma chemotherapy. You may be randomly assigned to one of the vaccine strategies, and the study checks your immune response.
AngersAges 18 years+ - NCT04731831Recruiting
Testing how well TNF medicines work in inflammatory arthritis
This study looks at how your immune system responds to starting infliximab or adalimumab for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Results may help doctors understand why some people don’t respond as well and how to improve treatment.
AalborgAges 18 years+ - NCT04875819RecruitingPhase 4
HIV vaccine safety check for meningitis and pneumonia shots
This trial studies how safe and how well the body’s immune system responds to meningococcal and pneumococcal vaccines in adults living with HIV. It may help confirm these vaccines work properly and are safe for people on HIV treatment.
HvidovreAges 18 years+ - NCT07536308RecruitingPhase 1
Nasal COVID-19 booster vaccine safety trial
This trial tests a new nasal spray COVID-19 booster vaccine. It aims to see if the vaccine is safe and produces a strong immune response when given through the nose and inhaled, in people who have already been vaccinated.
Decatur, GeorgiaAges 18–64 - NCT04975178RecruitingPhase 3
Test of a TB vaccine for newborns in sub-Saharan Africa
This Phase 3 study tests whether MTBVAC can safely protect newborn babies from tuberculosis and whether it helps the baby’s immune system learn to fight TB. If you enroll, the goal is to see safety and immune response in real newborn settings in sub-Saharan Africa.
Worcester, Western CapeAges 5 minutes–1 week - NCT05027776RecruitingPhase 3
HPV vaccine study for healthy girls and young women
This trial studies whether a quadrivalent HPV vaccine is safe and helps the body build protection (immunity) against HPV. It enrolls healthy Chinese females who are not already treated for HPV-related infection.
Mianyang, SichuanAges 9–26 - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT05422508RecruitingPhase 2
Second chickenpox shot for healthy kids after one prior vaccine
This study gives a second chickenpox vaccine dose to healthy children who were vaccinated once before. It mainly checks safety and measures the body’s immune response to see how well the second dose works.
AnsanAges 4–6 - NCT05554068RecruitingPhase 2
Testing the shingles vaccine response after bone marrow transplant
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
Maywood, IllinoisAges Any age - NCT05571735Recruiting
COVID vaccine immune response study in people with tuberculosis
This study measures how strongly your immune system responds to COVID-19 vaccines. It includes people with newly diagnosed tuberculosis and a healthier comparison group, aiming to understand vaccine immune effects and safety.
Mae Ramat, Changwat TakAges 18 years+ - NCT05580458RecruitingPhase 1/Phase 2
Shingles vaccine study for adults with well-controlled HIV
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
Bethesda, MarylandAges 18 years+ - NCT05697575Recruiting
Staphylokinase during stroke blood-flow treatment
This trial studies using a medication called non-immunogenic staphylokinase as part of standard clot-busting treatment for an acute ischemic stroke. It may help clinicians improve blood flow after the stroke using an approach designed to be less likely to trigger immune reactions.
Saint PetersburgAges 18–85 - NCT05859490RecruitingPhase 1/Phase 2
Yellow fever vaccine study for adults with past vaccination
This trial studies how well the yellow fever vaccine “17D” stimulates the immune system (the body’s germ-fighting response) in adults who were vaccinated with 17D years ago. It may help researchers understand whether a prior vaccination still provides protection and how strong the immune response is.
Portland, OregonAges 20–49 - NCT05947890RecruitingPhase 2
Testing an immune-boosting TB vaccine in people with or without HIV
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
Johannesburg, GautengAges 12–55 - NCT06044077RecruitingPhase 3
Testing a new pneumonia vaccine in healthy people
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
Chengdu, SichuanAges 2 years+ - NCT06126822RecruitingPhase 3
Study of Ebola vaccine booster in previously vaccinated adults
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
GomaAges 18–50 - NCT06137755RecruitingPhase 1
Shingles vaccine study for healthy adults 50-65
This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.
Seoul, Eunpyeong-guAges 50–64 - NCT06192576Recruiting
Long-term safety of olipudase alfa in young children with ASMD
This study looks at the long-term safety and how well the body accepts olipudase alfa therapy in children under 2 years old who have a certain type of ASMD. It helps understand if the treatment works safely over time.
Chicago, IllinoisAges Up to 2 years - NCT06205056RecruitingPhase 1
HIV vaccine safety and immune response test
This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.
KampalaAges 18–50 - NCT06255626RecruitingPhase 1/Phase 2
New COVID-19 booster vaccine study
This trial tests a new type of COVID-19 booster vaccine that targets a protein to help your immune system. It's for people who already had a primary vaccine series and at least one mRNA booster, with the last booster at least 6 months ago.
CréteilAges 18–84
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 149 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.